FDA Approval ProspectsThe path to FDA approval of Yutrepia for PAH/PH-ILD remains clear, with no active ongoing legal proceedings to impede it.
Legal VictoriesLegal developments continue to shift in Liquidia’s favor, with optimism for another win in the upcoming patent infringement hearing.
Market PotentialAnalyst maintains a Buy rating ahead of the near-term FDA approval of Yutrepia and its commercial launch in the expanding ~$2B inhaled treprostinil PAH/PH-ILD market.